Bristol Company Profile

✉ Email this page to a colleague

BRISTOL has one hundred and sixteen approved drugs.

There are fifty-five US patents protecting BRISTOL drugs.

There are one thousand six hundred and ninety-five patent family members on BRISTOL drugs in fifty-eight countries and three hundred and eleven supplementary protection certificates in nineteen countries.

International Patents:	1695
US Patents:	55
Tradenames:	93
Ingredients:	81
NDAs:	116
Drug Master File Entries:	1
Patent Litigation for Bristol:	See patent lawsuits for Bristol
PTAB Cases with Bristol as patent owner:	See PTAB cases with Bristol as patent owner

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol	ULTRACEF	cefadroxil/cefadroxil hemihydrate	FOR SUSPENSION;ORAL	062376-003	Mar 16, 1982		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Bristol	POMALYST	pomalidomide	CAPSULE;ORAL	204026-003	Feb 8, 2013		RX	Yes	No	8,198,262*PED	⤷ Sign Up			Y	⤷ Sign Up
Bristol Myers Squibb	SERZONE	nefazodone hydrochloride	TABLET;ORAL	020152-001	Dec 22, 1994		DISCN	Yes	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bristol Myers Squibb	SUSTIVA	efavirenz	TABLET;ORAL	021360-001	Feb 1, 2002	5,663,169*PED	⤷ Sign Up
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-005	Dec 21, 2011	8,626,531	⤷ Sign Up
Bristol Myers Squibb	PRAVACHOL	pravastatin sodium	TABLET;ORAL	019898-003	Oct 31, 1991	4,346,227*PED	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	0.5 mg and 1 mg	➤ Subscribe	2010-06-14
➤ Subscribe	Tablets	30 mg	➤ Subscribe	2005-06-01
➤ Subscribe	Tablets	80 mg and 140 mg	➤ Subscribe	2011-06-16
➤ Subscribe	Capsules	1 mg, 2 mg, 3 mg and 4 mg	➤ Subscribe	2017-02-08
➤ Subscribe	Capsules	50 mg and 100 mg	➤ Subscribe	2006-12-18
➤ Subscribe	Capsules	25 mg	➤ Subscribe	2010-07-12
➤ Subscribe	Capsules	150 mg	➤ Subscribe	2014-02-03
➤ Subscribe	Capsules	2.5 mg and 20 mg	➤ Subscribe	2016-07-12
➤ Subscribe	Injection	10 mg/vial	➤ Subscribe	2013-11-05
➤ Subscribe	Capsules	100 mg and 150 mg	➤ Subscribe	2010-03-19
➤ Subscribe	Tablets	600 mg	➤ Subscribe	2009-04-09
➤ Subscribe	Nasal Spray	4 mg/spray	➤ Subscribe	2016-07-15
➤ Subscribe	Tablets	2.5 mg and 5 mg	➤ Subscribe	2016-12-28
➤ Subscribe	Tablets	20 mg, 50 mg, 70 mg and 100 mg	➤ Subscribe	2010-06-28
➤ Subscribe	Tablets	80 mg and 140 mg	➤ Subscribe	2011-06-17
➤ Subscribe	Delayed-release Capsules	200 mg, 250 mg and 400 mg	➤ Subscribe	2004-06-01
➤ Subscribe	Capsules	200 mg	➤ Subscribe	2006-09-25
➤ Subscribe	Capsules	5 mg, 10 mg and 15 mg	➤ Subscribe	2010-08-30
➤ Subscribe	For Injection Suspension	100 mg/vial	➤ Subscribe	2015-12-11
➤ Subscribe	Capsules	300 mg	➤ Subscribe	2009-07-20
➤ Subscribe	Capsules	200 mg	➤ Subscribe	2010-02-16
➤ Subscribe	Capsules	50 mg, 100 mg and 200 mg	➤ Subscribe	2016-11-03

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2049506	300780	Netherlands	⤷ Sign Up	PRODUCT NAME: COBICISTAT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/13/830/001-002 20130527
1169038	300567	Netherlands	⤷ Sign Up	PRODUCT NAME: DASATINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/06/363/001 - 009 20061120
1951684	C202130029	Spain	⤷ Sign Up	PRODUCT NAME: FEDRATINIB, O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, O UN HIDRATO FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN PARTICULAR MONOHIDRATO DE DIHIDROCLORURO DE FEDRATINIB; NATIONAL AUTHORISATION NUMBER: EU/1/20/1514; DATE OF AUTHORISATION: 20210208; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1514; DATE OF FIRST AUTHORISATION IN EEA: 20210208
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.